Sector Gamma AS purchased a new position in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 148,092 shares of the biopharmaceutical company’s stock, valued at approximately $12,203,000. Clovis Oncology comprises about 1.9% of Sector Gamma AS’s holdings, making the stock its 18th largest holding. Sector Gamma AS owned 0.30% of Clovis Oncology at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Phocas Financial Corp. bought a new stake in shares of Clovis Oncology during the second quarter worth approximately $112,000. Capital Analysts LLC bought a new stake in shares of Clovis Oncology during the third quarter worth approximately $111,000. Advisors Asset Management Inc. raised its stake in shares of Clovis Oncology by 160.7% during the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 1,168 shares during the last quarter. Legato Capital Management LLC bought a new stake in shares of Clovis Oncology during the second quarter worth approximately $220,000. Finally, Bank of Montreal Can raised its stake in shares of Clovis Oncology by 284.9% during the second quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 2,000 shares during the last quarter. 98.53% of the stock is owned by institutional investors and hedge funds.
Clovis Oncology, Inc. (NASDAQ:CLVS) traded down $0.50 during mid-day trading on Wednesday, reaching $65.49. 1,074,300 shares of the company’s stock traded hands, compared to its average volume of 1,867,495. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.16 and a current ratio of 3.19. Clovis Oncology, Inc. has a 52-week low of $33.23 and a 52-week high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. The firm had revenue of $16.81 million during the quarter, compared to the consensus estimate of $21.12 million. During the same period in the prior year, the business earned ($1.70) earnings per share. equities research analysts forecast that Clovis Oncology, Inc. will post -7.31 earnings per share for the current fiscal year.
Several equities research analysts have commented on CLVS shares. Credit Suisse Group set a $107.00 target price on shares of Clovis Oncology and gave the company a “buy” rating in a research note on Tuesday, July 18th. Barclays PLC started coverage on shares of Clovis Oncology in a research note on Monday, October 23rd. They issued an “overweight” rating and a $105.00 target price for the company. Royal Bank Of Canada started coverage on shares of Clovis Oncology in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $81.00 target price for the company. Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Monday, September 11th. Finally, Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research note on Tuesday, October 17th. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $86.15.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $84.54, for a total value of $253,620.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 12.50% of the stock is owned by company insiders.
WARNING: This piece of content was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://sportsperspectives.com/2017/11/15/sector-gamma-as-purchases-shares-of-148092-clovis-oncology-inc-clvs.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.